Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Msci Inc (MSCI) Price & Performance

Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Msci Inc — how do they compare? Cassava Sciences Inc trades at $0.93 (market cap $47.75M), while Msci Inc trades at $563.93 (market cap $40.84B). The key difference: Msci Inc is far larger — about 855.3× Cassava Sciences Inc's market cap, and Msci Inc pays a 1.46% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAMSCI
Market Cap
$47.75M$40.84B
Sector
HealthFinancials
52-Week High
$4.64$643.83
52-Week Low
$0.87$511.84
Enterprise Value
-$34.93M$47.00B
Dividend Yield
1.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Msci Inc

MSCI trades at $559.73, down 0.59% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported Q2 2026 earnings of $4.94 per share, slightly missing expectations, but maintains strong fundamentals with a 40.73% net income margin and $3.13 billion in 2025 revenue. Recent developments include the completed acquisition of First Street and a strategic partnership with UBS to enhance private markets transparency.

The stock presents a compelling opportunity with a consensus price target of $728.14, implying significant upside, supported by robust profitability and recurring revenue streams. Key risks include high valuation multiples, such as a P/E of 30.71, and substantial long-term debt of $4.51 billion, which could pressure equity if interest rates rise.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Msci Inc

MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.

Read more on MSCI